BridgeMD
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.
EU CTIS ID: 2023-506617-21-00
What this study is testing
The primary objective is to compare the treatment response (baseline; visit 2 vs. end of treatment; visit 4), expressed as symptoms severity at six weeks and changes in symptom severity from baseline as measured by the Montgomery Åsberg Depression Rating Scale (MADRS) under an early-intensified pharmacological treatment to that under treatment as usual.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- In- or out patients, at least 18 years of age up until 65.
- Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure.
- Female participants of child bearing potential must use effective contraception during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation)
- Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2).
- Participant experiences a current treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3y; preferably this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs). However, other treatments are accepted.
- Participant and clinician intend to change pharmacotherapeutic treatment.
You likely can't join if
- Being pregnant or breastfeeding.
- Participants with active suicidal ideation with some intent to act, without specific plan (“Yes” to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent (“Yes” to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study
- Participant meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed.
- Participants dependent on the sponsor, investigator or trial site must be excluded from participation in advance.
- Participants have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- Participant has used (es)ketamine previously for the treatment of depressive symptoms.
See the full eligibility criteria
Who can join
- In- or out patients, at least 18 years of age up until 65.
- Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure.
- Female participants of child bearing potential must use effective contraception during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation)
- Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2).
- Participant experiences a current treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3y; preferably this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs). However, other treatments are accepted.
- Participant and clinician intend to change pharmacotherapeutic treatment.
- A minimum symptom severity threshold needs to be present (moderate level; see below) and participant needs to experience functional impairment. - The minimum symptom severity threshold is at least 2 PANSS positive or negative items with a score of 4, or at least one PANSS positive or negative item with a score of 5 - Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS).
What rules you out
- Being pregnant or breastfeeding.
- Participants with active suicidal ideation with some intent to act, without specific plan (“Yes” to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent (“Yes” to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study
- Participant meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed.
- Participants dependent on the sponsor, investigator or trial site must be excluded from participation in advance.
- Participants have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- Participant has used (es)ketamine previously for the treatment of depressive symptoms.
- Participant has a known intolerance to (es)ketamine or to all TAU medication options.
- Meeting any of the contraindications for (es)ketamine or to all TAU medication options, as specified within the applicable SmPC, supported by clinically significant abnormal values on local laboratory tests, electrocardiogram (ECG) or physical examinations.
- Participant has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1.
- Participant experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- United Kingdom
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; United Kingdom; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.